ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate | 863433-69-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate
• 英文别名: ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-(2-morpholin-4-yl-2-oxoethyl)-2-oxo-1,5-naphthyridine-3-carboxylate
• CAS: 863433-69-6
• 化学式: C₂₄H₂₄FN₃O₆
• 分子量: 469.469
• InChiKey: IMRMBSFVHLZPMZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  109
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  DL-氨基丙醇 、 ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate 在 二氯甲烷 、 盐酸 、 Brine 作用下， 生成 (+/-)-7-[(4-Fluorophenyl)methyl]-4-hydroxy-N-(2-hydroxy-1-methylethyl)-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide
  参考文献：
  名称：

  HIV INTEGRASE INHIBITORS

  摘要：

  本发明涉及一类HIV整合酶抑制剂化合物，因此可用于抑制HIV复制，预防和/或治疗HIV感染，并用于治疗艾滋病和/或ARC。

  公开号：

  US20150225399A1
• 作为产物：
  描述：

  N-{2-[(ethyloxy)carbonyl]-5-[(4-fluorophenyl)methyl]-3-pyridinyl}glycine 在 sodium ethanolate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-[2-(4-morpholinyl)-2-oxoethyl]-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate
  参考文献：
  名称：

  Combining symmetry elements results in potent naphthyridinone (NTD) HIV-1 integrase inhibitors

  摘要：

  A series of naphthyridinone HIV-1 integrase strand-transfer inhibitors have been designed based on a psdeudo-C2 symmetry element present in the two-metal chelation pharmacophore. A combination of two distinct inhibitor binding modes resulted in potent inhibition of the integrase strand-transfer reaction in the low nM range. Effects of aryl and N1 substitutions are disclosed including the impact on protein binding adjusted antiviral activity. (C) 2011 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2011.08.082

文献信息

• Hiv Integrase Inhibitors
  申请人：Johns Alvin Brian

  公开号：US20070124152A1

  公开（公告）日：2007-05-31

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明涉及一种HIV整合酶抑制剂化合物，因此在抑制HIV复制，预防和/或治疗HIV感染以及治疗艾滋病和/或ARC方面具有用途。
• 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors
  申请人：Johns Brian Alvin

  公开号：US08691991B2

  公开（公告）日：2014-04-08

  The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.

  本发明涉及能够抑制HIV整合酶的化合物，因此可用于抑制HIV复制，预防和/或治疗HIV感染，以及治疗艾滋病和/或ARC。
• Combining symmetry elements results in potent naphthyridinone (NTD) HIV-1 integrase inhibitors
  作者：Brian A. Johns、Takashi Kawasuji、Jason G. Weatherhead、Eric E. Boros、James B. Thompson、Edward P. Garvey、Scott A. Foster、Jerry L. Jeffrey、Wayne H. Miller、Noriyuki Kurose、Kenichi Matsumura、Tamio Fujiwara

  DOI：10.1016/j.bmcl.2011.08.082

  日期：2011.11

  A series of naphthyridinone HIV-1 integrase strand-transfer inhibitors have been designed based on a psdeudo-C2 symmetry element present in the two-metal chelation pharmacophore. A combination of two distinct inhibitor binding modes resulted in potent inhibition of the integrase strand-transfer reaction in the low nM range. Effects of aryl and N1 substitutions are disclosed including the impact on protein binding adjusted antiviral activity. (C) 2011 Published by Elsevier Ltd.
• US20140256713A1
  申请人：——

  公开号：——

  公开（公告）日：——
• US8691991B2
  申请人：——

  公开号：US8691991B2

  公开（公告）日：2014-04-08